Pharma faces a critical ‘turning point’ in 2026, years in the making

While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape.

By Michael Gibney • Nov. 21, 2025

How do Big Pharma employees rate their CEOs?

There are many ways to steer the ship as the top exec of a large pharma company. Here are the ones employees approve of the most — as well as those who could polish their image a little more.

By Alexandra Pecci • Nov. 20, 2025

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

RNAi looked doomed to fail — until Alnylam’s science chief found a way

Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.

By Michael Gibney • Nov. 13, 2025

After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing

Harout Semerjian, whose pedigree includes launching the Novartis cancer blockbuster Gleevec, is aiming to boost awareness about Geron’s Rytelo to give it momentum.

By Alexandra Pecci • Nov. 12, 2025

Why Pfizer and Novo are duking it out over weight loss startup Metsera

A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena’s high stakes.

By Michael Gibney • Nov. 6, 2025

How Trump’s do-or-die agenda is impacting Big Pharma’s CEO chatter

Among tariffs, pricing policies and ongoing negotiations, pharma leaders can’t help but address their dealings with the Trump administration in third-quarter earnings reports.

By Michael Gibney • Oct. 30, 2025

What comes next for Novo Nordisk?

After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is on Novo to pull off a major about-face.

By Kelly Bilodeau • Oct. 29, 2025

Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience

A premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at revolutionary technology that fits into their own expertise.

By Michael Gibney • Oct. 28, 2025

J&J’s orthopedics selloff keeps all eyes on a thriving pharma portfolio

As another J&J department bites the dust, leadership is focused on what’s working in the pharma business, and there’s plenty to see.

By Michael Gibney • Oct. 16, 2025

Overcoming past mistakes, generics powerhouse Teva embraces an innovative ‘mindset change’

In the three years since a leadership change, Teva has evolved its R&D approach beyond a long history making copycat medicines.

By Michael Gibney • Oct. 7, 2025

With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs?

The only woman to head up a company in Big Pharma is stepping down from the role at the end of the year.

By Meagan Parrish • Oct. 3, 2025

Top pharma industry conferences in 2026

Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.

By Meagan Parrish • Oct. 1, 2025

Why drugmakers may need to borrow from quantum theory to confront tariff and pricing threats

With so many unknowns surrounding regulatory and policy shifts, pharma companies might need to consider fundamental changes to how they operate, a Deloitte analyst said.

By Michael Gibney • Sept. 3, 2025

How AI advances will shape the drugmaker of the future

An AI revolution is taking place, and leaders from tech to Big Pharma are forecasting what drugmakers of the future will look like.

By Michael Gibney • Sept. 2, 2025

FDA’s new accelerated pathway could open pharma up to risks, as well as benefits

Faster review times will leave drugmakers vulnerable to litigation, while new Trump administration priorities add more uncertainty in the drug approval process.

By Amy Baxter • Aug. 25, 2025

Merck KGaA ventures into new territory in the US

How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.

By Alexandra Pecci • Aug. 15, 2025

Let’s make a deal? Big Pharma execs express varying views on their M&A future

Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.

By Michael Gibney • Aug. 5, 2025

C-suite shuffles ripple through pharma

Novo Nordisk, Kenvue and Jazz Pharmaceuticals announced changes at the top this month.

By Meagan Parrish • July 31, 2025

Dr. Vinay Prasad, controversial FDA official, abruptly departs agency

Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got embroiled in controversy over a Duchenne gene therapy.

By Ben Fidler • July 30, 2025

Who is Dr. George Tidmarsh, the new director of CDER?

Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.

By Meagan Parrish and Michael Gibney • July 23, 2025

J&J accelerates past Stelara’s fall with better-than-expected portfolio growth

Stelara is faltering due to biosimilar entries, but J&J execs demonstrate they were ready to fill the gap all along.

By Michael Gibney • July 17, 2025

Need a DTC platform? Here’s how one company built its own.

Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med. 

By Amy Baxter • July 14, 2025

As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

Simone Steiner recently joined the French company to set the stage for launch.  

By Amy Baxter • July 9, 2025

A biopharma bolsters patient centricity and trial diversity goals through newly created role

Ardelyx’s newly minted chief patient officer is infusing patient experiences into every element of the business.

By Alexandra Pecci • July 1, 2025

AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all

The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.

By Michael Gibney • July 1, 2025